Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation
Circulation · 29.10.2024 · 150 (18) · 1401-1411
DOI: 10.1161/circulationaha.124.068613 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Circulation, erschienen am 29.10.2024. Verfasst von Kasper Bonnesen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Clinical Epidemiology (K.B., U.H.-J., D.H.C., L.P., R.W.T., M.S.), Aarhus University Hospital, Denmark. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Empagliflozin and dapagliflozin have proven cardiovascular benefits in people with type 2 diabetes at high cardiovascular risk, but their comparative effectiveness is unknown. METHODS: This study used nationwide, population-based Danish health registries to emulate a hypothetical target trial comparing empagliflozin versus dapagliflozin initiation, in addition to standard care, among people with treated type 2 diabetes from 2014 through 2020. The outcome was a composite of myocardial infarction, ischemic stroke, heart failure (HF), or cardiovascular death (major adverse cardiovascular event). Participants were followed until an outcome, emigration, or death occurred; 6 years after initiation; or December 31, 2021, whichever occurred first. Logistic regression was used to compute inverse probability of treatment and censoring weights, controlling for 57 potential confounders. In intention-to-treat analyses, 6-year adjusted risks, risk differences, and risk ratios, considering noncardiovascular death competing events, were estimated. Analyses were stratified by coexisting atherosclerotic cardiovascular disease and HF. A per-protocol design was performed as a secondary analysis. RESULTS: There were 36 670 eligible empagliflozin and 20 606 eligible dapagliflozin initiators. In the intention-to-treat analysis, the adjusted 6-year absolute risk of major adverse cardiovascular event was not different between empagliflozin and dapagliflozin initiators (10.0% versus 10.0%; risk difference, 0.0% [95% CI, −0.9% to 1.0%]; risk ratio, 1.00 [95% CI, 0.91 to 1.11]). The findings were consistent in people with atherosclerotic cardiovascular disease (risk difference, −2.3% [95% CI, −8.2% to 3.5%]; risk ratio, 0.92 [95% CI, 0.74 to 1.14]) and without atherosclerotic cardiovascular disease (risk difference, 0.3% [95% CI, −0.6% to 1.2%]; risk ratio, 1.04 [95% CI, 0.93 to 1.16]) and in people with HF (risk difference, 1.1% [95% CI, −6.5% to 8.6%]; risk ratio, 1.04 [95% CI, 0.79 to 1.37]) and without HF (risk difference, −0.1% [95% CI, −1.0% to 0.8%]; risk ratio, 0.99 [95% CI, 0.90 to 1.09]). The 6-year risks of major adverse cardiovascular event were also not different in the per-protocol analysis (9.1% versus 8.8%; risk difference, 0.2% [95% CI, −2.1% to 2.5%]; risk ratio, 1.03 [95% CI, 0.80 to 1.32]). CONCLUSIONS: Empagliflozin and dapagliflozin initiators had no differences in 6-year cardiovascular outcomes in adults with treated type 2 diabetes with or without coexisting atherosclerotic cardiovascular disease or HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Clinical Epidemiology (K.B., U.H.-J., D.H.C., L.P., R.W.T., M.S.), Aarhus University Hospital, Denmark.
- Department of Clinical Medicine, Aarhus University, Denmark (K.B., U.H.-J., D.H.C., L.P., R.W.T., M.S.).
- Endocrinology and Internal Medicine (D.H.C.), Aarhus University Hospital, Denmark.
- Department of Epidemiology, Rollins School of Public Health, Emory University, GA (T.L.L.).
- Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, PA (S.H.).
- Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Sweden (A.M.).
ORCID-Profile: Kasper Bonnesen, Uffe Heide-Jørgensen, Diana H Christensen, Sean Hennessy, Anthony Matthews, Lars Pedersen, Reimar W Thomsen, Morten Schmidt
Zitieren
APA
Bonnesen, K., Heide-Jørgensen, U., Christensen, D. H., Lash, T. L., Hennessy, S., Matthews, A., Pedersen, L., Thomsen, R. W., & Schmidt, M. (2024). Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation. Circulation, 150(18), 1401-1411. https://doi.org/10.1161/circulationaha.124.068613
Vancouver
Bonnesen K, Heide-Jørgensen U, Christensen DH, Lash TL, Hennessy S, Matthews A, et al. Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation. Circulation. 2024;150(18):1401-1411. doi:10.1161/circulationaha.124.068613
BibTeX
@article{Bonnesen2024,
author = {Bonnesen, Kasper and Heide-Jørgensen, Uffe and Christensen, Diana H and Lash, Timothy L and Hennessy, Sean and Matthews, Anthony and Pedersen, Lars and Thomsen, Reimar W and Schmidt, Morten},
title = {Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation},
journal = {Circulation},
year = {2024},
volume = {150},
number = {18},
pages = {1401--1411},
doi = {10.1161/circulationaha.124.068613}
}
EUVIMED